

GALECTIN THERAPEUTICS INC  
Form 8-K  
February 14, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

February 14, 2012

Date of Report (Date of earliest event reported)

**GALECTIN THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Charter)

NEVADA  
(State or Other Jurisdiction)

000-32877  
(Commission)

04-3562325  
(IRS Employer)

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

(State of Incorporation)

(File Number)  
7 WELLS AVENUE

(Identification No.)

NEWTON, MASSACHUSETTS

02459

(Address of Principal Executive Offices) (Zip Code)

(617) 559-0033

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

Peter G. Traber, M.D., President and Chief Executive Officer of Galectin Therapeutics, Inc. ( Company ), is presenting a corporate update at the BIOCEO & Investor Conference on February 14, 2012 contained in the slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K (this Report ).

The information in this Report is being furnished pursuant to this Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Report.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Corporate Update Presentation Slides - dated February 14, 2012.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GALECTIN THERAPEUTICS, INC.

By: /s/ Anthony Squeglia  
Anthony Squeglia  
Chief Financial Officer

Date: February 14, 2012

**Exhibit Index**

**Exhibit**

**Number**

99.1 Corporate Update Presentation Slides dated February 14, 2012.